Quick Answer
Semaglutide is FDA-approved for adolescents aged 12+ with obesity (Wegovy). The STEP TEENS trial demonstrated 16.1% BMI reduction compared to 0.6% with placebo. Side effect profiles were similar to adults: nausea, vomiting, and diarrhea were most common. Growing body considerations include ensuring adequate nutrition for development (protein, calcium, iron, vitamins), monitoring growth trajectory, and addressing the psychological impact of weight management medication during formative years. Parental involvement and age-appropriate counseling are essential. The decision to treat should balance the health consequences of untreated adolescent obesity against the limited long-term safety data in this age group. FormBlends evaluates adolescent patients with input from parents and pediatric providers.
Medical Disclaimer: This article is for informational purposes only. Discuss all treatment decisions with your healthcare provider, particularly for special populations.
STEP TEENS Trial Data
The STEP TEENS trial enrolled 201 adolescents aged 12 to 17 with obesity. After 68 weeks, semaglutide 2.4mg produced a mean BMI reduction of 16.1% compared to 0.6% with placebo. The side effect profile mirrored adult trials: GI symptoms were most common, with nausea (36%), diarrhea (19%), and vomiting (15%) being the most frequent.
Discontinuation due to adverse events was 5.3% with semaglutide versus 0% with placebo, comparable to adult rates. No unexpected safety signals emerged in the adolescent population. Growth velocity was not significantly affected during the trial period, though longer-term data on pubertal development is limited.
Growing Body Considerations
Adolescents are still growing, and any treatment that reduces caloric intake must be monitored for effects on growth and development. Height velocity should be tracked at every visit. Pubertal stage should be assessed periodically. Bone density concerns are theoretical (reduced calcium intake during weight loss could affect bone accrual), though not demonstrated in the STEP TEENS data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →FormBlends monitors growth parameters alongside weight for all adolescent patients. If growth velocity slows unexpectedly, caloric intake and nutritional adequacy are assessed immediately. The treatment approach is more conservative in younger teens (12 to 14) who have more growth remaining than older teens (16 to 17).
Nutritional Needs During Development
Adolescents on semaglutide need more nutritional attention than adults. Minimum protein intake should be 60 to 80 grams daily to support both weight loss and ongoing muscle and tissue development. Calcium (1300mg daily for teens) and vitamin D (600 to 1000 IU) are critical for bone development. Iron needs are elevated during adolescence, especially in menstruating females.
A daily multivitamin designed for teens is recommended as nutritional insurance. Protein shakes can supplement dietary protein when appetite is significantly reduced. FormBlends includes nutritional counseling specific to the adolescent population. See our supplement guide for general supplement guidance.
Psychological Impact
Weight management medication during adolescence carries unique psychological dimensions. Body image is forming during these years, and the experience of taking a weight loss medication can affect self-perception both positively and negatively. Some teens feel empowered by effective treatment. Others may feel stigmatized or dependent.
Open communication between the teen, parents, and provider is essential. Therapy or counseling alongside semaglutide treatment can help teens develop a healthy relationship with food, body image, and medical treatment. The goal is not only a number on the scale but the development of sustainable healthy habits and positive self-concept.
What Parents Should Know
Parents should be involved in all treatment decisions but must respect the teen's developing autonomy. Monitor for adequate eating and hydration without creating food anxiety. Watch for signs of disordered eating patterns that could develop in the context of appetite suppression. Ensure the teen is not skipping meals entirely. Maintain open, non-judgmental conversations about how they feel physically and emotionally. Attend provider visits together.
Community Perspectives
r/Semaglutide: "My 14-year-old started Wegovy - parent perspective"
234 upvotes, 189 comments
A parent described their decision to start semaglutide for their 14-year-old after years of unsuccessful lifestyle interventions. The teen lost 30 pounds over 6 months with mild nausea during the first 2 weeks. Confidence improved dramatically. The parent emphasized working with a pediatric endocrinologist and a therapist throughout. Commenters debated the ethics and appropriateness, with most supporting evidence-based treatment for adolescent obesity.
Top comment: "We tried everything else first. Medication was the last option and the first thing that actually worked for my kid."
Clinical gap: Long-term safety data for semaglutide in adolescents beyond 68 weeks is not yet available. Effects on pubertal development, final adult height, bone density, and psychological development during extended treatment are unknown and require ongoing study.
Frequently Asked Questions
Is semaglutide approved for teens?
Yes. Wegovy is FDA-approved for adolescents aged 12+ with obesity (BMI at or above 95th percentile).
What are the side effects in teens?
Similar to adults: nausea (36%), diarrhea (19%), vomiting (15%). Most are temporary and resolve within 1 to 2 weeks.
Will it affect growth?
STEP TEENS showed no significant effect on growth velocity at 68 weeks. Monitor height at every visit. Long-term data is limited.
What nutrition do teens need on semaglutide?
60 to 80g protein, 1300mg calcium, 600+ IU vitamin D, adequate iron, and a teen multivitamin daily.
Should my teen see a therapist too?
Recommended. Therapy supports healthy body image, food relationship, and emotional processing during treatment.